Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)
for
Cystic Fibrosis
Location: Birmingham AL, Aurora CO, Denver CO, Wilmington DE,
Sponsor: Boston Children's Hospital
Sex: All
Age: 6+
Code: NCT06683092
Recruiting
Active & ResponsiveNew
Investigation of Lymph Node Biology in Kidney Cancer
for
Renal Cell Carcinoma (RCC)
Location: New Haven CT
Sponsor: Yale University
Sex: All
Age: 18+
Code: NCT07038733
Recruiting
Active & Responsive
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
for
Solid Tumors, Gastric Cancer,
Location: Santa Monica CA, Santa Rosa CA, Greenville SC,
Sponsor: EMD Serono Research & Development Institute, Inc.
Sex: All
Age: 18+
Code: NCT06710132
Phase1, Phase2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.
for
Metastatic Pancreatic Cancer
Location: Baltimore MD
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sex: All
Age: 18+
Code: NCT04753879
Phase2, Recruiting
Active & Responsive
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
for
Solid Tumor, Adult, Colorectal Cancer,
Location: Gilbert AZ, Phoenix AZ, La Jolla CA, Palo Alto CA,
Sponsor: A2 Biotherapeutics Inc.
Sex: All
Age: 18+
Code: NCT04981119
Recruiting
Active & Responsive
A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
for
Pancreatic Adenocarcinoma, Resectable Pancreatic Cancer
Location: Columbus OH
Sponsor: Ashish Manne
Sex: All
Age: 18+
Code: NCT05624918
Phase2, Recruiting
Active & Responsive
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
for
Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer,
Location: Duarte CA, Miami FL, Gainesville GA, New Albany IN,
Sponsor: Adela, Inc
Sex: All
Age: 40+
Code: NCT05366881
Recruiting
Active & Responsive
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
for
Triple Negative Breast Cancer (TNBC),
Location: Denver CO, Boston MA, Grand Rapids MI, New York NY,